Companies /Healthcare
Adc Therapeutics SA
NYSE: ADCT Drug Manufacturers - Specialty & Generic
$1.55
▲ $0.01 (+0.32%) today
Markets open · 3:50pm ET

ADC Therapeutics SA (ADCT) Q1 2026 Earnings

Reported May 4, 2026, 7:43am ET · SEC source
$-0.13
Beat +35.55%
EPS · est. $-0.20
$20.9M
Beat +4.32%
Revenue · est. $20.0M
−69.6%
Trailing market
ADCT vs S&P since report
4 quarters
Consecutive EPS beats

How Did ADCT Stock React to Q1 2026 Earnings?

% change · around the report
−4%0+4%+8%May 4May 5report 7:43am ETearnings+0.7%−2.8%
−4%0+4%+8%May 4May 5earnings+0.7%−2.8%
ADCT −2.8%S&P 500 +0.7%
−4%0+4%+8%May 4May 5report 7:43am ETearnings+1.3%−2.8%
−4%0+4%+8%May 4May 5earnings+1.3%−2.8%
ADCT −2.8%NASDAQ +1.3%
−5%0+5%+10%May 4May 12report 7:43am ETearnings+2.5%−6.7%
−5%0+5%+10%May 4May 12earnings+2.5%−6.7%
ADCT −6.7%S&P 500 +2.5%
−5%0+5%+10%May 4May 12report 7:43am ETearnings+5.1%−6.7%
−5%0+5%+10%May 4May 12earnings+5.1%−6.7%
ADCT −6.7%NASDAQ +5.1%
−3.92%
Day of report
+2.17%
Next session
−5.43%
One week
−64.13%
30 days

S&P 500 over the same 30 days: +5.44%.

Did ADCT Beat Earnings? Q1 2026 Results

Yes. ADC Therapeutics SA reported Q1 2026 earnings of $-0.13 a share on May 4, 2026, beating the $-0.20 consensus estimate by 35.5%. Revenue was $20.9M against a $20.0M estimate.

ADC Therapeutics delivered a stronger-than-expected first quarter for fiscal 2026, posting a loss of $0.13 per share against a consensus estimate of $0.20, a beat of 35.55%, while revenue of $20.85 million edged past the $19.99 million analyst forecast by 4.32%. Total revenue fell 9.5% year over year, largely because the prior-year period included a one-time partner milestone that inflated license revenues; stripping that out, net product revenues for ZYNLONTA grew 15% to $20.03 million, reflecting higher pricing and stronger unit volumes. The narrower loss was also driven by a $9.05 million reduction in R&D expenses as discontinued programs and completed IND-enabling work lowered external costs. Management maintained its cash runway guidance of at least into 2028, with $231.01 million on hand, and investors are closely watching for topline data from the LOTIS-5 Phase 3 confirmatory trial, expected by the end of June, which could support an sBLA submission before year-end and potentially unlock a significantly broader addressable market for ZYNLONTA across B-cell malignancies.

Key Takeaways
  • ZYNLONTA product revenue growth driven by higher volume and pricing
  • R&D expense reduction of $9 million due to discontinued programs and completed IND-enabling activities
  • Personnel cost reallocation from R&D to commercial manufacturing and selling activities

“During the first quarter, we continued to build momentum across our ZYNLONTA program. Looking ahead, we have multiple near-term catalysts, including topline results from LOTIS-5 anticipated in the second quarter, full results expected from both LOTIS-5 and LOTIS-7 by year-end, as well as additional updates from the investigator-initiated studies in indolent lymphomas ahead. We believe that we are well-positioned to expand ZYNLONTA's role across B-cell malignancies, accelerating our expected growth trajectory starting in 2027.”

ADC Therapeutics SA CEO, on the earnings call

What Was ADC Therapeutics SA's Outlook in Q1 2026?

ADC Therapeutics expects LOTIS-5 Phase 3 topline results in Q2 2026, with full results from both LOTIS-5 and LOTIS-7 anticipated by year-end 2026. If LOTIS-5 is positive, the company intends to submit an sBLA to the FDA before year-end, targeting potential compendia inclusion in H1 2027 and confirmatory approval in 2L+ DLBCL thereafter. Investigator-initiated trial data in follicular lymphoma and marginal zone lymphoma are expected between late 2026 and mid-2027. The company projects cash runway at least into 2028 and anticipates accelerating its growth trajectory starting in 2027.

ADCT YoY Financials

Q1 2026 vs Q1 2025 · SEC filings Q1 2025 Q1 2026
$-20,000,000$0$20.0M$23.0M$20.9MRevenue$21.0M$17.2MGross Profit$-22,679,903$-25,245,000Operating Income$-28,767,888$-32,968,000Net Income
$-20,000,000$0$20.0MRevenueGross ProfitOperating IncomeNet Income
ADCT income statement, Q1 2026 versus Q1 2025
Metric Q1 2026 Q1 2025 Year over year
Revenue $20.9M $23.0M −9.5%
Gross Profit $17.2M $21.0M −17.8%
Operating Income −$25.2M −$22.7M +11.3%
Net Income −$33.0M −$28.8M +14.6%

ADCT Revenue by Segment

ZYNLONTA (Product Revenue)
ZYNLONTA Product Revenue$20.0M
ZYNLONTA
ZYNLONTA (Product Revenues)
License Revenues and Royalties$818,000

Figures from SEC filings and company reports. Not investment advice.